AJCP / Meeting AbstrActs atypical cells. The small atypical lymphocytes were positive for CD20, PAX5, CD79a, OCT.2, CD10, BCL-2, and BCL-6, and negative for T-cell markers. The large atypical cells in the diffuse areas were positive for CD30, CD2, CD3, CD5, CD7, MUM-1, partially positive for CD4 and CD8 in addition to CD20, PAX5, CD79a, and OCT.2. Epstein-Barr virus was positive in the diffuse large B-cell lymphoma but not follicular lymphoma by in situ hybridization for Epstein-Barr virus-encoded RNAs. Both the large and small atypical lymphocytes were negative for CD15, TCR gamma, TCR beta, TIA1, granzyme B, and perforin. Polymerase chain reaction revealed a clonal immunoglobulin heavy chain gene rearrangement and polyclonal T-cell receptor gamma gene rearrangement. Further positron emission tomography study revealed left neck and abdominal involvement. A biopsy of the retroperitoneal mass showed low-grade follicular lymphoma. The patient was treated with rituximab; however, he worsened clinically. At last discharge, he suffered from recurrent pleural effusions and a new lung mass suspicious for metastatic squamous cell carcinoma. Large B-cell lymphoma with rearrangements of MYC, BCL2, and BCL6, so-called "triple-hit" lymphoma, now designated as high-grade B-cell lymphoma (HGBL), with MYC and BCL2 and/or BCL6 rearrangements per World Health Organization classification, is an aggressive, rare malignancy typically affecting older adults. We report a case in an 87-year-old Caucasian man who presented with a rapidly enlarging, 14.9 cm chest wall mass. MRI also showed chest and axillary lymphadenopathy and a lesion in left humeral head. Histologic sections of chest mass demonstrated an atypical lymphoid infiltrate with intermediate to large cells showing stippled to vesicular chromatin, brisk mitoses and punctate necrosis. Immunohistochemistry showed positivity for CD20, CD10, BCL-2, and BCL-6 in lymphoid cells. In situ hybridization (ISH) for kappa and lambda demonstrated kappa light chain restriction. MIB-1 was high (80%). Fluorescence ISH demonstrated MYC, BCL-2, and BCL-6 rearrangements. The diagnosis of HGBL, with rearrangements of MYC, BCL2, and BCL6, was rendered. The patient received chemotherapy with bendamustine and rituximab, and has been in remission for 7.5 months. Triple-hit lymphomas are not frequently reported; thus, the incidence is unknown. However, it is important to document this entity as it has distinct prognostic and therapeutic implications. Currently, the challenge is how to adequately screen for this entity. Many institutions perform molecular studies on any B-cell lymphoma showing features intermediate between DLBCL and BL, a MIB-1 >90%, or any DLBCL refractory to therapy. Others suggest limiting studies to cases of germinal center origin and/or high-grade morphology or to cases with > 40% MYC+ cells. MYC immunohistochemistry can also help identify double-expressor lymphomas, defined by coexpression of MYC and BCL2 by IHC, which are associated with a worse prognosis than other LBCLs, but may not behave as aggressively as double/triple-hit lymphomas (HGBLs).
Large B-cell lymphoma with rearrangements of MYC, BCL2, and BCL6, so-called "triple-hit" lymphoma, now designated as high-grade B-cell lymphoma (HGBL), with MYC and BCL2 and/or BCL6 rearrangements per World Health Organization classification, is an aggressive, rare malignancy typically affecting older adults. We report a case in an 87-year-old Caucasian man who presented with a rapidly enlarging, 14.9 cm chest wall mass. MRI also showed chest and axillary lymphadenopathy and a lesion in left humeral head. Histologic sections of chest mass demonstrated an atypical lymphoid infiltrate with intermediate to large cells showing stippled to vesicular chromatin, brisk mitoses and punctate necrosis. Immunohistochemistry showed positivity for CD20, CD10, BCL-2, and BCL-6 in lymphoid cells. In situ hybridization (ISH) for kappa and lambda demonstrated kappa light chain restriction. MIB-1 was high (80%). Fluorescence ISH demonstrated MYC, BCL-2, and BCL-6 rearrangements. The diagnosis of HGBL, with rearrangements of MYC, BCL2, and BCL6, was rendered. The patient received chemotherapy with bendamustine and rituximab, and has been in remission for 7.5 months. Triple-hit lymphomas are not frequently reported; thus, the incidence is unknown. However, it is important to document this entity as it has distinct prognostic and therapeutic implications. Currently, the challenge is how to adequately screen for this entity. Introduction: Dural marginal zone lymphoma (DMZL) is a very rare type of central nervous system lymphoma that does not involve brain parenchyma. The differential diagnosis includes meningiomas and metastasis, which can make the diagnosis difficult. DMZL has been considered indolent lymphoma in the literature. Here we report additional two new cases of DMZL; one had transformation to diffuse large B-cell lymphoma (DLBCL), while the other had complex cytogenetics, indicating the potential for DLBCL transformation, and genetics associated with unfavorable prognosis for this unusual lymphoma location. Methods: Routine histology, flow cytometry immunophenotyping, immunohistochemistry, karyotyping, and FISH analysis were employed for these two cases. Results: Histologic findings are slightly different in these two cases. Besides morphologic changes consistent with a marginal zone lymphoma, one case had areas of sheet of large transformed cells, which suggested transformation to DLBCL, as illustrated by high Ki-67 proliferation index up to 80%-90% in the large cell areas. Flow cytometry detected a population of kappa-restricted monoclonal B cells without CD5 or CD10 for both cases. Karyotyping for the second patient showed that of the 20 cells analyzed, eight were normal, and 12 had multiple clonal abnormalities including a del 6q, additional material of unknown origin attached to 17q, and an unbalanced structural rearrangement involving an 18q resulting in 18q deletion and duplication of 1q (karyotyping: 46,XX,del(6)(q21q23),add(17)(q25),der(18)t(1;18) (q21;q23) [12]/46, XX[8] ). FISH probes for c-MYC, BCL-2, BCL-6, and CCND1 were all negative for both cases. The first patient with DLBCL was treated with adjuvant radiation therapy after the completion of chemotherapy. The patient with complex karyotyping was found local recurrence after surgical mass removal for which she had received local radiation therapy. Both patients are still alive. Conclusions: DMZL, although considered a low-grade lymphoma, may have DLBCL transformation or complex cytogenetics, despite the unusual location.
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Howell-Jolly Body-Like Inclusions in Neutrophils of Patients With Myelodysplastic Syndrome: A Novel Correlation
Yi Tat Tong, Andy Nguyen, MD, Amer Wahed, MD; University of Texas, Houston
Objectives: Howell-Jolly body-like inclusions (HJBLIs) have been classically associated with human immunodeficiency virus (HIV)-infected patients, patients on antiviral medications, and immunosuppressed individuals. These inclusions appear in neutrophils, and unlike Barr bodies, are completely detached inclusions in the cytoplasm. They are thought to represent detached nuclear fragments produced from dysplastic granulopoiesis. To the best of our knowledge, no association of HJBLIs and myelodysplastic syndrome (MDS) has been reported previously. Here we establish an unprecedented correlation of HJBLIs in patients with, MDS. Interestingly, in all 11 cases, none of the patients has a history of HIV or was on immunosuppressants and antiviral medications. Methods: A total of 11 bone marrow cases from patients diagnosed with, MDS,, MDS/myeloproliferative neoplasm (MPN), and acute myeloid leukemia (AML) with, MDS-related changes were studied. Detailed medical records review was performed to ensure none of the 11 patients had a history of HIV or was on immunosuppressants and antiviral medications. Peripheral blood and bone marrow aspirate smears were reviewed. Results: Seven out of 11 (64%) cases show detached intracytoplasmic inclusions in mature neutrophils consistent with HJBLIs. They were also seen in myelocytes in one of the 11 cases. Conclusion: In review of literatures, HJBLIs seem to correlate with immunosuppression and antiviral therapies with nucleoside analogs. The morphology of HJBLIs can be easily confused with other intracytoplasmic inclusions, such as large leukocyte granules found in Chédiak-Higashi syndrome. We propose that the formation of HJBLIs is the consequence of dysplasia and hence its correlation with, MDS. The inclusions are, however, seen in only a minority of white cells (<1%), which is probably why they were not brought to practicing pathologists' awareness in the past. The findings from this study would contribute important data to more future scientific research to determine the exact mechanism of HJBLI formation. Plasma cell neoplasms (PCNs) are lymphoproliferative disorders arising from post germinal center B cells with somatic hypermutations that exhibit varied manifestations and can be a challenging diagnosis for clinicians and pathologists. A subset of PCN reveals translocations of chromosome 14 involving the immunoglobulin heavy chain locus (IgH) with specific clinicopathological features with prognostic implications that have not been well characterized. We present to you the case of a 69-year-old man with mid back pain that radiated to his chest. Imaging of the thoracic spine revealed heterogeneous enhancement of both T6 and T11 vertebrae, after which he underwent a CT-guided biopsy of the T6 vertebra. The touch preparation and core biopsy revealed extensive infiltration by small-sized plasmacytic cells in a paratrabecular pattern. Immunohistochemistry revealed these cells to be positive for CD138, CD20, Bcl-2, MUM1, and cyclin D1, and negative for CD45, CD3, CD5, CD10, and Bcl-6. In situ hybridization (ISH) for kappa and lambda demonstrated lambda light chain restriction leading to a diagnosis of plasmacytic neoplasm with features most consistent with a CD20-positive plasmacytoma/myeloma. Fluorescence ISH revealed polysomy of odd-numbered chromosomes, chromosome 17 abnormalities, and the CCND1/IGH fusion gene in 71% of the examined cells. Although CD20 positivity in PCN with t(11,14) is well documented and has considerable therapeutic implications, it becomes very difficult to distinguish the present case from a B-cell lymphoma with plasmacytic features. Some studies show a worse prognosis for translocation-associated PCN, while other studies do not support this finding. Since PCNs present with heterogeneous morphology, clinical features, and immunohistochemical and molecular profiles, extensive work-up and clinicopathologic correlation is essential for appropriate classification and management.
